Trial Profile

A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Onureg®) in Subjects With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Adult Subjects With Myeloid Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

24 Jun 2025 Planned End Date changed from 1 Jun 2025 to 30 Jun 2025.
24 Jun 2025 Planned primary completion date changed from 1 Jun 2025 to 30 Jun 2025.
24 Jun 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com